It's time to develop personalized cell therapies for the care of chronic wounds.
​Therapy for Chronic Wounds
​Healiva® is a patient-centric Swiss Biotech company developing personalized therapies to improve patients’ quality of life. We are advancing a multi-pronged approach to address patient needs by integrating cell therapies, enzyme technology, and medical devices to create tailored solutions for chronic wounds. As the first Biotech to develop multiple end-to-end, intuitive wound care products, we ensure they remain both personalized and affordable.
Mission
Our mission is to develop a portfolio of innovative, personalized, and affordable therapies for chronic wounds, addressing key pain points in the patient care pathway. A major gap remains in the current treatment paradigm, as no permanent therapy for non-healing wounds currently exists. We are actively developing solutions to bridge this gap and transform wound care.
Wounds: A sizeable problem
156M
Chronic wound patients worldwide
​
2-3% of the elderly have painful Venous/Arterial Leg Ulcers
25% of diabetics have disabling diabetic foot ulcers
9.7M
Venous leg ulcers and
10M
Diabetic Foot ulcers patients
€21.7B
in 2022 according to PitchBook Data
8%
CAGR by 2026
Pipeline Products
Healiva Technological Breakthroughs
Healiva products
Indication
Pre-clinical discovery
Pre-clinical development
Ph I/IIa
Ph IIb
Ph III
Market phase
AQUAtryp
Acute & chronic wounds
Healiva 004
VLUs chronic wounds
Healiva 002
VLUs chronic wounds
Epidex
Severe VLUs / chronic wounds
